PHARMACEUTICAL FORMULATION COMPRISING AMORPHOUS OR THERMODYNAMICALLY METASTABLE RIVAROXABAN

摘要

The present invention relates to a pharmaceutical formulation including, as an active ingredient, a high dose (preferably, 15 or 20 mg) of 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidine-5-yl}-methyl]-2-thiophene carboxamide (rivaroxaban) having increased solubility in an amorphous or thermodynamically metastable crystal form, wherein the pharmaceutical drug has reduced variation in absorption (bioavailability) depending on food intake.